Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q1

7446.TEDINET S100Q8CO
Period2022-10-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥9.4bn2022-10-01 → 2022-12-31Cons.Net sales
Revenue¥37.3bn2021-10-01 → 2022-09-30Cons.Net sales (5-year summary)
Revenue¥9.0bn2021-10-01 → 2021-12-31Cons.Net sales
Operating income¥254m2022-10-01 → 2022-12-31Cons.Operating income
Operating income¥214m2021-10-01 → 2021-12-31Cons.Operating income
Ordinary income¥271m2022-10-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.0bn2021-10-01 → 2022-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥229m2021-10-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥271m2022-10-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥229m2021-10-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥182m2022-10-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥658m2021-10-01 → 2022-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥148m2021-10-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥187m2022-10-01 → 2022-12-31Cons.Profit loss
Net income¥155m2021-10-01 → 2021-12-31Cons.Profit loss
Total assets¥19.2bnat 2022-12-31Cons.Assets
Total assets¥17.5bnat 2022-09-30Cons.Assets
Total assets¥18.1bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥12.5bnat 2022-12-31Cons.Liabilities
Total liabilities¥10.8bnat 2022-09-30Cons.Liabilities
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.3bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥2.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥1.4bnat 2022-09-30Cons.Cash and deposits
EPS (basic)¥202.312022-10-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥728.762021-10-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.692021-10-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio34.7%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio37.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.6%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2022-10-01 → 2022-12-31¥17m
Otherother segmentsrevenue external2022-10-01 → 2022-12-31¥17m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue2022-10-01 → 2022-12-31¥866m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue external2022-10-01 → 2022-12-31¥866m
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue2022-10-01 → 2022-12-31¥4.6bn
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2022-10-01 → 2022-12-31¥4.6bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue2022-10-01 → 2022-12-31¥4.0bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2022-10-01 → 2022-12-31¥4.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-10-01 → 2022-12-31¥9.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-10-01 → 2022-12-31¥9.4bn
Otherother segmentsrevenue2021-10-01 → 2021-12-31¥20m
Otherother segmentsrevenue external2021-10-01 → 2021-12-31¥20m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2021-12-31¥823m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2021-12-31¥823m
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2021-12-31¥4.4bn
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2021-12-31¥4.4bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2021-12-31¥3.8bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2021-12-31¥3.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2021-12-31¥9.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2021-12-31¥9.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 369
ItemContextValueUnit
Valuation and translation adjustmentsPrior1YearInstant578255000JPY
Valuation and translation adjustmentsCurrentQuarterInstant546986000JPY
Non controlling interestsPrior1YearInstant76384000JPY
Non controlling interestsCurrentQuarterInstant80647000JPY
Net assetsPrior1YearInstant6681448000JPY
Net assetsCurrentQuarterInstant6733108000JPY
Liabilities and net assetsPrior1YearInstant17519610000JPY
Liabilities and net assetsCurrentQuarterInstant19188477000JPY
Net salesPrior1YTDDuration9042324000JPY
Net salesCurrentYTDDuration9409299000JPY
Cost of salesPrior1YTDDuration8202483000JPY
Cost of salesCurrentYTDDuration8539838000JPY
Gross profitPrior1YTDDuration839841000JPY
Gross profitCurrentYTDDuration869460000JPY
Selling general and administrative expensesPrior1YTDDuration625576000JPY
Selling general and administrative expensesCurrentYTDDuration615021000JPY
Operating incomePrior1YTDDuration214264000JPY
Operating incomeCurrentYTDDuration254439000JPY
Interest income noiPrior1YTDDuration917000JPY
Interest income noiCurrentYTDDuration855000JPY
Dividends income noiPrior1YTDDuration10965000JPY
Dividends income noiCurrentYTDDuration14148000JPY
Commission fee noiPrior1YTDDuration1458000JPY
Commission fee noiCurrentYTDDuration2337000JPY
Other noiPrior1YTDDuration4056000JPY
Other noiCurrentYTDDuration2366000JPY
Non operating incomePrior1YTDDuration17398000JPY
Non operating incomeCurrentYTDDuration19707000JPY
Interest expenses noePrior1YTDDuration308000JPY
Interest expenses noeCurrentYTDDuration405000JPY
Commission fee noePrior1YTDDuration2167000JPY
Commission fee noeCurrentYTDDuration2124000JPY
Other noePrior1YTDDuration410000JPY
Other noeCurrentYTDDuration207000JPY
Non operating expensesPrior1YTDDuration2886000JPY
Non operating expensesCurrentYTDDuration2737000JPY
Ordinary incomePrior1YTDDuration228777000JPY
Ordinary incomeCurrentYTDDuration271409000JPY
Gain on sales of investment securities eiPrior1YTDDuration206000JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration206000JPY
Extraordinary incomeCurrentYTDDuration－JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration53000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration53000JPY
Extraordinary lossCurrentYTDDuration－JPY
Income before income taxesPrior1YTDDuration228930000JPY
Income before income taxesCurrentYTDDuration271409000JPY
Income taxes currentPrior1YTDDuration58331000JPY
Income taxes currentCurrentYTDDuration67391000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-09-30pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass